Stress is a primary risk factor for several neuropsychiatric disorders. Evidence from
preclinical models and clinical studies of depression have revealed an array of structural …

Investigations in the last 10 years have revealed a new category of neurological diseases
mediated by antibodies against cell surface and synaptic proteins. There are currently 16 …

In patients with major depressive disorder or bipolar disorder, abnormalities in excitatory
and/or inhibitory neurotransmission and neuronal plasticity may lead to aberrant functional …

Depression is a multicausal disorder and has been associated with the risk to develop
cancer, dementia, diabetes, epilepsy and stroke. As a metabolic disorder depression has …

Traditional antidepressants require many weeks to reveal their therapeutic effects. However,
the widely replicated observation that a single subanesthetic dose of the N-methyl-D …

Major depressive disorder (MDD) is a common, chronic, recurrent mental illness that affects
millions of individuals worldwide. To date, the monoaminergic systems (serotonin …

The discovery of allosteric modulators of G protein-coupled receptors (GPCRs) provides a
promising new strategy with potential for developing novel treatments for a variety of central …

Chronic stress accounts for billions of dollars of economic loss annually in the United States
alone, and is recognized as a major source of disability and mortality worldwide. Robust …

The mechanisms of action of the rapid antidepressant effects of ketamine, an N-methyl-D-
aspartate glutamate receptor antagonist, have not been fully elucidated. This study …

The N-methyl-D-aspartate receptor antagonist ketamine can improve major depressive
disorder (MDD) within hours. To evaluate the putative role of glutamatergic and GABAergic …